Journal
ADDICTION BIOLOGY
Volume 12, Issue 1, Pages 35-50Publisher
BLACKWELL PUBLISHING
DOI: 10.1111/j.1369-1600.2007.00051.x
Keywords
acamprosate; alcohol self-administration; baclofen; dopamine D-3 receptors; naltrexone; SB-277011A
Categories
Funding
- NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000473, Z01DA000473] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The present study examined the effects of the acute intraperitoneal (i.p.) administration of the selective dopamine (DA) D-3 receptor antagonist SB-277011A (10, 20 or 30 mg/kg i.p.) on the oral operant self-administration of alcohol in male C57BL/6N mice. These effects were compared with those of naltrexone (0.5, 1 and 2 mg/kg i.p.) and acamprosate (100, 200 and 400 mg/kg i.p.). Compared with vehicle, the acute administration of SB-277011A (10 or 20 mg/kg) did not significantly alter the operant self-administration of alcohol, whereas the 30 mg/kg dose significantly reduced alcohol intake (g/kg), the number of reinforcers, and the number of active lever presses. The oral self-administration of alcohol was not significantly altered by the acute administration of either naltrexone or acamprosate, compared with vehicle-treated mice. SB-277011A, naltrexone and acamprosate were also tested in a model of drug/cue-triggered reinstatement of alcohol-seeking behavior. In this model, neither naltrexone (2 mg/kg) nor acamprosate (400 mg/kg) prevented relapse to alcohol-seeking behavior. In contrast, SB-277011A significantly reduced reinstatement of alcohol seeking in a dose-dependent manner. Provided these results can be extrapolated to humans, they suggest that selective DA D-3 receptor antagonists may be useful in the harmacotherapeutic management of alcohol intake and prevention of relapse to alcohol-seeking behavior.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available